Receive a copy of our current research models and services product guide.
Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.
Reduce costs with our complimentary sample for evaluation in your lab.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
April 5-10, 2024 San Diego, CA Booth #3729 The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from p...
May 6-10, 2024 San Antonio, TX Booth #TBD Each year WRIB program provides you with novel case studies and emerging approaches because it is the only p...
May 7-11, 2024 Baltimore, MD Booth #830 Join the Inotiv team at the American Society of Gene and Cell Therapy’s (ASGCT) annual meeting, the premier ev...
February 07, 2024 – First quarter fiscal 2024 revenue up 10.3% to $135.5 mi...
January 29, 2024 WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a lea...
December 11, 2023 — Fiscal year 2023 revenue up 4.5% to $572.4 millio...
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2024 Inotiv. All Rights Reserved.